Related Experiment Video
Updated: Jun 3, 2026
06:33
Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Published on: November 10, 2023
Gene expression profiling in MDS and AML: potential and future avenues
K Theilgaard-Mönch1, J Boultwood, S Ferrari
1Biotech Research and Innovation Centre & Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Leukemia
|March 30, 2011
Summary
Gene expression profiling refines the classification of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This technology aids in diagnosis, predicting outcomes, and identifying new treatments for these myeloid malignancies.
Area of Science:
- Hematology
- Genomics
- Molecular Biology
Background:
- Current myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) classifications integrate genetic aberrations but miss cases and show clinical heterogeneity.
- Unidentified genetic and epigenetic factors contribute to MDS/AML heterogeneity, necessitating advanced molecular characterization.
Purpose of the Study:
- To review how gene expression profiling (GEP) refines the molecular taxonomy of MDS and AML.
- To explore GEP's role in diagnosis, outcome prediction, subclass discovery, and therapeutic target identification for myeloid malignancies.
Main Methods:
- Comprehensive literature review on the application of gene expression profiling (GEP) in MDS and AML research.
- Analysis of GEP's contribution to understanding molecular mechanisms and clinical heterogeneity in myeloid malignancies.
Main Results:
- GEP enhances the molecular classification of MDS and AML by revealing aberrant gene expression patterns.
- GEP facilitates improved diagnosis, prognostication, identification of novel disease subclasses, and discovery of therapeutic targets and drugs.
Conclusions:
- GEP is a powerful tool for molecularly characterizing MDS and AML, improving classification and guiding treatment strategies.
- Future integrative genomics studies hold potential for further understanding myeloid malignancies and developing individualized therapies.
